Inbrain's Graphene Brain Interface: First Human Trial Results Signal a New Class of Neural Device

A graphene cortical interface has cleared its first human safety trial. Inbrain Neuroelectronics reported no device-related adverse events across 8 patients implanted in its Phase I trial, a meaningful safety milestone for a technology that has been theoretically compelling but clinically unproven. For the field of brain-computer interfaces, the result matters less for what the device does today and more for what it demonstrates: that graphene-based neural recording is safe enough in humans to build from.

Note: This post covers early-stage clinical research. Brain-computer interfaces are investigational medical devices. Consult a qualified healthcare provider before making any decisions based on emerging neurotechnology research.

Context

Conventional neural implants are fabricated from silicon and metal — rigid, relatively thick, and prone to generating scar tissue over time as the brain reacts to the foreign material. Graphene’s appeal as a neural interface material is structural: it can be deposited in extremely thin, flexible layers that conform to cortical tissue rather than pressing against it. The theoretical biocompatibility advantage has been documented in animal models for years; the Inbrain trial is the first to establish human safety data.

The trial ran under NCT06368310, conducted at the University of Manchester in partnership with the Northern Care Alliance NHS Foundation Trust. It enrolled 10 patients, with 8 receiving implants — a standard Phase I design focused on safety and tolerability rather than therapeutic efficacy. The use case was awake neurosurgery: patients undergoing brain surgery while conscious, where neural recording is used for real-time speech mapping to guide surgeons away from eloquent cortex.

The Detail

The 8 implanted patients completed the trial with no device-related adverse events across a 90-day monitoring period. Inbrain’s graphene cortical interface was used during awake craniotomy procedures, recording neural signals to assist surgeons in identifying speech-critical brain regions in real time. This is an existing clinical workflow — the innovation is in the recording material, not the surgical procedure itself.

Graphene interfaces record at a different resolution than conventional electrodes. The material’s electrical properties allow it to detect local field potentials and individual neuron firing across finer spatial scales, which matters for high-resolution brain mapping. Whether that resolution advantage translates to measurably better surgical outcomes is a question for subsequent trial phases; the Phase I data establishes only that the device is safe to deploy.

Inbrain’s lead researcher on the trial is Mark Hersam of Northwestern University — the same lab behind recent work on printed electronics using MoS₂ and graphene inks, which also appeared in Nature Nanotechnology. The graphene neuroscience research community is small and interconnected, and the same material properties driving printed neural circuits are being applied here in vivo.

Results from the 90-day monitoring period are expected to be published later in 2026.

Source: Longevity.Technology

Content created with AI assistance and reviewed for accuracy.